REPORT ID 3025

United States Anthrax Vaccines Market Report 2017

Publish Date
12-Dec-17
Pages
120
Format
Electronic (PDF)

In this report, the United States Anthrax Vaccines market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Anthrax Vaccines in these regions, from 2012 to 2022 (forecast).

United States Anthrax Vaccines market competition by top manufacturers/players, with Anthrax Vaccines sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Agrovet
    Bayer Sanidad Animal
    Biog?nesis-Bago S.A.
    Botswana Vaccine Institute
    CAVAC
    Central Veterinary Control and Research Institute
    Centro Diagn?stico Veterinario
    Ceva Sante Animale
    Colorado Serum Company
    Empresa Colombiana de Productos Veterinarios S.A. (Vecol)
    Indian Immunologicals Limited
    Institute for Biological Products
    Institute of Animal Health and Veterinary Biologicals
    Institute of Veterinary Preventive Medicine
    Instituto Rosenbusch S.A.
    Institutul Pasteur
    Intervac (PVT) Ltd.
    Jordan Bio-Industries Center (JOVAC)
    KAKETSUKEN (Chemo-Sero-Therapeutic Research Institute)
    Laboratorio Prondil S.A.
    Laboratorios Laverlam S.A.
    Merial Argentina

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Cell Free PA Vaccines: Anthrax Vaccine Adsorbed (AVA) , Anthrax Vaccine Precipitated (AVP)
    Live Vaccines
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Human
    Animals

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Anthrax Vaccines Market Report 2017
1 Anthrax Vaccines Overview
    1.1 Product Overview and Scope of Anthrax Vaccines
    1.2 Classification of Anthrax Vaccines by Product Category
        1.2.1 United States Anthrax Vaccines Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Anthrax Vaccines Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 Cell Free PA Vaccines: Anthrax Vaccine Adsorbed (AVA) , Anthrax Vaccine Precipitated (AVP)
        1.2.4 Live Vaccines
    1.3 United States Anthrax Vaccines Market by Application/End Users
        1.3.1 United States Anthrax Vaccines Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Human
        1.3.3 Animals
    1.4 United States Anthrax Vaccines Market by Region
        1.4.1 United States Anthrax Vaccines Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Anthrax Vaccines Status and Prospect (2012-2022)
        1.4.3 Southwest Anthrax Vaccines Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Anthrax Vaccines Status and Prospect (2012-2022)
        1.4.5 New England Anthrax Vaccines Status and Prospect (2012-2022)
        1.4.6 The South Anthrax Vaccines Status and Prospect (2012-2022)
        1.4.7 The Midwest Anthrax Vaccines Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Anthrax Vaccines (2012-2022)
        1.5.1 United States Anthrax Vaccines Sales and Growth Rate (2012-2022)
        1.5.2 United States Anthrax Vaccines Revenue and Growth Rate (2012-2022)

2 United States Anthrax Vaccines Market Competition by Players/Suppliers
    2.1 United States Anthrax Vaccines Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Anthrax Vaccines Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Anthrax Vaccines Average Price by Players/Suppliers (2012-2017)
    2.4 United States Anthrax Vaccines Market Competitive Situation and Trends
        2.4.1 United States Anthrax Vaccines Market Concentration Rate
        2.4.2 United States Anthrax Vaccines Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Anthrax Vaccines Manufacturing Base Distribution, Sales Area, Product Type

3 United States Anthrax Vaccines Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Anthrax Vaccines Sales and Market Share by Region (2012-2017)
    3.2 United States Anthrax Vaccines Revenue and Market Share by Region (2012-2017)
    3.3 United States Anthrax Vaccines Price by Region (2012-2017)

4 United States Anthrax Vaccines Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Anthrax Vaccines Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Anthrax Vaccines Revenue and Market Share by Type (2012-2017)
    4.3 United States Anthrax Vaccines Price by Type (2012-2017)
    4.4 United States Anthrax Vaccines Sales Growth Rate by Type (2012-2017)

5 United States Anthrax Vaccines Sales (Volume) by Application (2012-2017)
    5.1 United States Anthrax Vaccines Sales and Market Share by Application (2012-2017)
    5.2 United States Anthrax Vaccines Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Anthrax Vaccines Players/Suppliers Profiles and Sales Data
    6.1 Agrovet
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Anthrax Vaccines Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Agrovet Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Bayer Sanidad Animal
        6.2.2 Anthrax Vaccines Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Bayer Sanidad Animal Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Biog?nesis-Bago S.A.
        6.3.2 Anthrax Vaccines Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Biog?nesis-Bago S.A. Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Botswana Vaccine Institute
        6.4.2 Anthrax Vaccines Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Botswana Vaccine Institute Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 CAVAC
        6.5.2 Anthrax Vaccines Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 CAVAC Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Central Veterinary Control and Research Institute
        6.6.2 Anthrax Vaccines Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Central Veterinary Control and Research Institute Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Centro Diagn?stico Veterinario
        6.7.2 Anthrax Vaccines Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Centro Diagn?stico Veterinario Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Ceva Sante Animale
        6.8.2 Anthrax Vaccines Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Ceva Sante Animale Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Colorado Serum Company
        6.9.2 Anthrax Vaccines Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Colorado Serum Company Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Empresa Colombiana de Productos Veterinarios S.A. (Vecol)
        6.10.2 Anthrax Vaccines Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Empresa Colombiana de Productos Veterinarios S.A. (Vecol) Anthrax Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Indian Immunologicals Limited
    6.12 Institute for Biological Products
    6.13 Institute of Animal Health and Veterinary Biologicals
    6.14 Institute of Veterinary Preventive Medicine
    6.15 Instituto Rosenbusch S.A.
    6.16 Institutul Pasteur
    6.17 Intervac (PVT) Ltd.
    6.18 Jordan Bio-Industries Center (JOVAC)
    6.19 KAKETSUKEN (Chemo-Sero-Therapeutic Research Institute)
    6.20 Laboratorio Prondil S.A.
    6.21 Laboratorios Laverlam S.A.
    6.22 Merial Argentina

7 Anthrax Vaccines Manufacturing Cost Analysis
    7.1 Anthrax Vaccines Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Anthrax Vaccines

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Anthrax Vaccines Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Anthrax Vaccines Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Anthrax Vaccines Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Anthrax Vaccines Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Anthrax Vaccines Sales Volume Forecast by Type (2017-2022)
    11.3 United States Anthrax Vaccines Sales Volume Forecast by Application (2017-2022)
    11.4 United States Anthrax Vaccines Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer